---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-050349"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:40:29.286193+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH

## Summary
- In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.
- In NHL monotherapy, 38% ORR across subtypes; in PTCL, 44% ORR and 19% complete metabolic response rate.
- Neutropenia manageable; no discontinuations due to neutropenia; MTD not yet reached.
- Next steps: complete Phase 1 dose escalation, initiate combo trials, engage regulators on path.
- Data support potential best-in-class IKZF1/3 degrader for MM and NHL.

## SEC filing metadata
- accession: 0001628280-24-050349
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/0001628280-24-050349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/cccc-20241209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-050349
- JSON: https://secwatch.observer/filing/0001628280-24-050349.json
- Plain text: https://secwatch.observer/filing/0001628280-24-050349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.